NO20034278L - Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner - Google Patents

Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner

Info

Publication number
NO20034278L
NO20034278L NO20034278A NO20034278A NO20034278L NO 20034278 L NO20034278 L NO 20034278L NO 20034278 A NO20034278 A NO 20034278A NO 20034278 A NO20034278 A NO 20034278A NO 20034278 L NO20034278 L NO 20034278L
Authority
NO
Norway
Prior art keywords
methods
compositions
hcv
treating hcv
hcv infections
Prior art date
Application number
NO20034278A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034278D0 (no
Inventor
Ann Kwong
Randal Byrn
Lola M Reid
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20034278D0 publication Critical patent/NO20034278D0/no
Publication of NO20034278L publication Critical patent/NO20034278L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/18—Liver cell growth factor (LCGF, Gly-His-Lys)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Semiconductor Lasers (AREA)
NO20034278A 2001-03-27 2003-09-25 Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner NO20034278L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27917401P 2001-03-27 2001-03-27
PCT/US2002/009685 WO2002077206A1 (en) 2001-03-27 2002-03-27 Compositiona and methods useful for hcv infection

Publications (2)

Publication Number Publication Date
NO20034278D0 NO20034278D0 (no) 2003-09-25
NO20034278L true NO20034278L (no) 2003-11-25

Family

ID=23067944

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034278A NO20034278L (no) 2001-03-27 2003-09-25 Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner

Country Status (14)

Country Link
US (3) US7879606B2 (de)
EP (1) EP1381673B1 (de)
JP (2) JP4499990B2 (de)
KR (1) KR100947911B1 (de)
CN (1) CN100362095C (de)
AT (1) ATE431396T1 (de)
CA (1) CA2441688C (de)
DE (1) DE60232322D1 (de)
ES (1) ES2328466T3 (de)
MX (1) MXPA03008882A (de)
NO (1) NO20034278L (de)
NZ (1) NZ528462A (de)
WO (1) WO2002077206A1 (de)
ZA (1) ZA200307373B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP3000899A1 (de) 2002-12-04 2016-03-30 Applied Biosystems, LLC Multiplexverstärkung von polynucleotiden
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
AU2004295702A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Compositions comprising fetal liver cells and methods useful for HCV infection
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
GEP20125645B (en) 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
AU2008333953B2 (en) * 2007-12-04 2014-01-09 Prionics Ag Kit and method for detecting bovine viral diarrhea virus in tissue samples
CN101906487A (zh) * 2010-08-05 2010-12-08 中国兽医药品监察所 一种猪瘟病毒核酸标准物质的制备方法
SG11201501505WA (en) * 2012-08-31 2015-03-30 Univ Alberta Methods for producing cells having a phenotype of a primary human hepatocytes and compositions
US10988737B2 (en) 2015-04-28 2021-04-27 Universite De Strasbourg Clinical gene signature-based human cell culture model and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529920A (en) * 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
US5849686A (en) 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6069005A (en) 1991-08-07 2000-05-30 Albert Einstein College Of Medicine Of Yeshwa University Hapatoblasts and method of isolating same
AU667680B2 (en) 1991-08-07 1996-04-04 Albert Einstein College Of Medicine Of Yeshiva University Proliferation of hepatocyte precursors
ATE318075T1 (de) 1993-11-19 2006-03-15 Einstein Coll Med Hepatoblasten und verfahren zu ihrer isolierung
DE69626022T3 (de) * 1995-08-01 2008-05-08 Sanofi Pasteur Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
CA2217266A1 (en) * 1997-05-14 1998-11-14 The General Hospital Corporation Co-cultivation of cells in a micropatterned configuration
FR2775983B1 (fr) * 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc Milieu et procede de propagation et de multiplication virales
EP0972828A1 (de) 1998-06-24 2000-01-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren zur in vitro Replikation von HCV
EP1975243B1 (de) * 1998-12-07 2010-03-24 Duke University BODIPY Aminoacetaldehyd Diethyl Acetal
KR100873690B1 (ko) 1999-01-19 2008-12-12 유니버시티 오브 노스캐롤라이나 앳 채플 힐 인간 간 전구세포
US20020187133A1 (en) 1999-10-01 2002-12-12 Hiroshi Kubota Methods of isolating bipotent hepatic progenitor cells
EP1252293B1 (de) 2000-01-19 2012-10-03 University Of North Carolina At Chapel Hill Herkunft von lebergewebe
CN1461341A (zh) 2000-10-03 2003-12-10 北卡罗来纳大学 肝祖先细胞克隆生长的方法
JP2004510432A (ja) 2000-10-03 2004-04-08 ユニバーシティ　オブ　ノース　カロライナ 両能性肝前駆細胞の単離方法
CN1592794A (zh) 2001-03-09 2005-03-09 加利福尼亚大学董事会 用于合成感染性丙型肝炎病毒的细胞培养系统
WO2004003172A2 (en) * 2002-07-01 2004-01-08 Pharmacia Corporation Esm-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same

Also Published As

Publication number Publication date
WO2002077206A1 (en) 2002-10-03
EP1381673B1 (de) 2009-05-13
ZA200307373B (en) 2005-06-29
JP2010142249A (ja) 2010-07-01
WO2002077206A9 (en) 2004-02-19
KR100947911B1 (ko) 2010-03-17
JP4499990B2 (ja) 2010-07-14
US8211696B2 (en) 2012-07-03
ATE431396T1 (de) 2009-05-15
EP1381673A1 (de) 2004-01-21
JP2004529637A (ja) 2004-09-30
CA2441688A1 (en) 2002-10-03
US20020142449A1 (en) 2002-10-03
NZ528462A (en) 2005-11-25
MXPA03008882A (es) 2003-12-08
DE60232322D1 (de) 2009-06-25
US20110229874A1 (en) 2011-09-22
EP1381673A4 (de) 2004-11-10
KR20040012739A (ko) 2004-02-11
US20130071834A1 (en) 2013-03-21
ES2328466T3 (es) 2009-11-13
US7879606B2 (en) 2011-02-01
CN1511190A (zh) 2004-07-07
CA2441688C (en) 2014-01-21
CN100362095C (zh) 2008-01-16
HK1063334A1 (en) 2004-12-24
NO20034278D0 (no) 2003-09-25

Similar Documents

Publication Publication Date Title
NO20034278D0 (no) Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner
DE60230672D1 (de) Nukleinsäureanreicherung
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
DE60232234D1 (de) Verfahren zur kultivierung von circovirus
MXPA06011046A (es) Ciertos compuestos basados en triazol, composiciones, y usos de los mismos.
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
MY142777A (en) Substituted indole-o-glucosides
ATE548391T1 (de) Gefangene bindungsproteine als biosensoren
UA87991C2 (en) Substituted indole-o-glucosides
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
TW200732349A (en) Anti-OX40L antibodies and methods using same
DK1261368T3 (da) Tværbunden, ikke-fungal lipaseholdig sammensætning og fremgangsmåder til anvendelse deraf
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
DE60230327D1 (de) Polymorphe von clopidogrel-hydrogensulfat
WO2006116127A3 (en) Compositions for use in identification of bacteria
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE256677T1 (de) Inhibitoren der bakteriellen nad synthetase
WO2010042551A3 (en) Methods for providing cellular lysates from cell wall-containing samples
NO20055741D0 (no) Nye kjemiske forbindelser
NO20053595L (no) Escitalopramdibromid samt fremgangsmate ved fremstilling derav.
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
BRPI0415285A (pt) derivados de aminoalcanol
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
DE60107718D1 (de) Konservierung von zellen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application